Market Dashboard

Snapshot View

Interactive Charts

Latest Market Commentary

Weekly Market Commentary | November 25th, 2024

Nov 25, 2024

Week in Review... Markets rallied last week as investors digested positive economic data and election results. The major indices all reached new record highs: The S&P 500 rose +1.68% The Dow Jones Industrial Average was up +1.96% The tech-heavy Nasdaq finished...

Market Commentary | November 18th, 2024

Nov 18, 2024

Week in Review... Markets retreated last week as investors reassessed potential tariff implications as well as concerns around inflation reaccelerating. The S&P 500 fell 2.08%, ending a multi-week positive streak The Dow Jones Industrial Average was down 1.24% The...

Market Commentary | November 11th, 2024

Nov 11, 2024

Week in Review... Following the highly anticipated U.S. election and rate cut decision by the Fed, last week saw equity market’s rally after the election of Donald Trump as the 47th president of the United States. The S&P 500 rose 4.66%, snapping a two-week...

Market Commentary | November 4th, 2024

Nov 4, 2024

Week in Review... With this past week being the last full week before investors go to the election polls, labor market numbers and inflation were the focus as markets struggled to overcome a surprise in payroll numbers. The S&P 500 fell 1.37%, continuing a...

« Older Entries

Next Entries »

Latest Market News from Around the Web

Personal Finance

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
February 21, 2025
The FDA's decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
UnitedHealth's rough stretch continues, with buyouts, a reported DOJ probe and a 23% drop in three months
February 21, 2025
It extends a tumultuous period for UnitedHealth marked by the killing of a top executive, a costly cyberattack against its subsidiary and high medical costs.
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
February 21, 2025
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Yankees throw out one of baseball's most notorious traditions: Players can now grow beards
February 21, 2025
For the first time in nearly 50 years, the New York Yankees are allowing players to grow "well-groomed beards."

Investment

Top Wall Street analysts are bullish on these dividend stocks
February 23, 2025
TipRanks' analyst ranking service highlights three dividend-paying stocks, including McDonald's and Ares Capital.
Westinghouse sees path to building cheaper nuclear plants after costly past
February 23, 2025
Two nuclear projects in the South were bogged down by costly overruns, but Westinghouse Electric Company still sees the potential for new U.S. plants.
Alibaba shares have soared on China AI hopes. Here’s where analysts see the stock heading next
February 23, 2025
E-commerce giant Alibaba felt the drag of China's consumer slowdown and heightened competition. Now it's a favored stock for playing China's AI trend.
As trade tensions simmer, these are the stocks with the most to lose — based on region
February 23, 2025
President Donald Trump's tariffs on imported goods have investors on edge as they could pressure a slew of companies regardless of sector.

Stock Market

Stocks making the biggest moves midday: UnitedHealth, Alibaba, Hims & Hers Health, Celsius and more
February 21, 2025
These are the stocks posting the largest moves in midday trading.
Stocks making the biggest moves premarket: UnitedHealth, Rivian, Block, Celsius and more
February 21, 2025
These are the stocks posting the largest moves in premarket trading.
Stocks making the biggest moves after hours: Celsius, Dropbox, Block and more
February 20, 2025
See which stocks are posting big moves after the bell.
Stocks making the biggest midday moves: Palantir, AppLovin, Shake Shack, Walmart and more
February 20, 2025
These are some of the stocks posting the largest moves in midday trading.

Useful Resources & Links

Check the background of investment professionals on FINRA’s BrokerCheck.

Securities offered through Registered Representatives of Cambridge Investment Research, Inc., a broker-dealer, member FINRA/SIPC. Advisory services through Cambridge Investment Research Advisors, Inc., a Registered Investment Advisor. Cambridge and River City Financial are not affiliated. This communication is strictly intended for individuals residing in the states of AL, FL, KY, ME, NC, NJ, OH, SC, TX, VA, WA, WI and WV. No offers may be made or accepted from any resident outside the specific states referenced.

Cambridge’s Form CRS (Customer Relationship Summary)

The information being provided is strictly as a courtesy. When you link to any of these websites provided herein, River City Financial makes no representation as to the completeness or accuracy of information provided at these sites. Nor is the company liable for any direct or indirect technical or system issues or any consequences arising out of your access to or your use of third-party technologies, sites, information, and programs made available through this site.

River City Financial